CONTE, Pierfranco
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 48.532
AS - Asia 18.805
EU - Europa 18.326
SA - Sud America 2.837
Continente sconosciuto - Info sul continente non disponibili 388
AF - Africa 387
OC - Oceania 45
Totale 89.320
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 47.616
GB - Regno Unito 5.652
SG - Singapore 5.430
CN - Cina 5.169
IT - Italia 4.258
HK - Hong Kong 2.294
BR - Brasile 2.167
VN - Vietnam 1.752
SE - Svezia 1.511
DE - Germania 1.311
BD - Bangladesh 1.228
UA - Ucraina 1.122
FI - Finlandia 1.100
IE - Irlanda 930
TR - Turchia 769
RU - Federazione Russa 656
FR - Francia 636
KR - Corea 463
CA - Canada 456
IN - India 427
BG - Bulgaria 397
ID - Indonesia 246
AR - Argentina 212
MX - Messico 174
IQ - Iraq 139
JP - Giappone 138
NL - Olanda 128
EC - Ecuador 102
CO - Colombia 100
ZA - Sudafrica 97
PL - Polonia 95
AE - Emirati Arabi Uniti 91
ES - Italia 89
PK - Pakistan 82
BE - Belgio 80
VE - Venezuela 75
PH - Filippine 65
MY - Malesia 63
CL - Cile 61
JM - Giamaica 56
CR - Costa Rica 54
SA - Arabia Saudita 54
UZ - Uzbekistan 54
PY - Paraguay 49
MA - Marocco 47
LT - Lituania 44
AU - Australia 43
EG - Egitto 38
NP - Nepal 37
CZ - Repubblica Ceca 36
KE - Kenya 35
AT - Austria 34
JO - Giordania 34
HN - Honduras 33
TH - Thailandia 32
AL - Albania 29
TN - Tunisia 29
IR - Iran 27
AZ - Azerbaigian 25
ET - Etiopia 25
HU - Ungheria 25
UY - Uruguay 25
TW - Taiwan 24
DZ - Algeria 23
RO - Romania 23
BO - Bolivia 22
RS - Serbia 22
DO - Repubblica Dominicana 21
PE - Perù 21
CH - Svizzera 20
IL - Israele 19
TT - Trinidad e Tobago 19
NI - Nicaragua 18
PT - Portogallo 18
KZ - Kazakistan 17
LB - Libano 17
OM - Oman 17
GR - Grecia 16
NG - Nigeria 16
GT - Guatemala 14
SN - Senegal 14
EE - Estonia 13
PR - Porto Rico 13
SI - Slovenia 13
SK - Slovacchia (Repubblica Slovacca) 12
BH - Bahrain 11
SV - El Salvador 11
BB - Barbados 10
CI - Costa d'Avorio 10
EU - Europa 10
KG - Kirghizistan 10
PA - Panama 10
QA - Qatar 10
SY - Repubblica araba siriana 10
BW - Botswana 9
MD - Moldavia 9
PS - Palestinian Territory 9
AM - Armenia 8
DK - Danimarca 8
AO - Angola 7
Totale 88.800
Salva come PNG Salva come JPEG
Città #
Ashburn 5.059
Fairfield 4.174
Southend 3.802
Singapore 3.515
Santa Clara 3.130
Woodbridge 3.075
Houston 2.637
Jacksonville 2.298
Hong Kong 2.261
Chandler 2.037
Ann Arbor 1.737
San Jose 1.656
Dearborn 1.572
Seattle 1.556
Wilmington 1.530
Hefei 1.526
Cambridge 1.377
Council Bluffs 1.150
Beijing 1.032
London 944
Dublin 924
Nyköping 827
Los Angeles 784
Helsinki 711
Chicago 644
Modena 642
The Dalles 640
New York 594
Ho Chi Minh City 587
Milan 500
Princeton 444
San Diego 436
Seoul 430
Hanoi 396
Sofia 381
Eugene 379
Izmir 364
Columbus 335
Lauterbourg 319
Buffalo 307
São Paulo 234
Salt Lake City 227
Rome 217
Shanghai 213
Dallas 210
Des Moines 208
Moscow 203
Boardman 188
Phoenix 170
Jakarta 150
Falls Church 143
Munich 141
Frankfurt am Main 122
Tampa 118
Elk Grove Village 117
Bologna 109
Toronto 102
Atlanta 100
Naples 99
Tokyo 97
Norwalk 94
Orem 87
Guangzhou 85
Da Nang 80
Denver 77
Turin 75
Brussels 72
Florence 72
Haiphong 71
Lancaster 66
Miano 66
Brooklyn 65
Warsaw 64
Mexico City 63
Chennai 62
Redwood City 60
Rio de Janeiro 57
Montreal 55
Dong Ket 54
Sterling 54
Fremont 53
Philadelphia 53
Belo Horizonte 51
Nanjing 51
Porto Alegre 51
Brasília 50
Boston 49
Bremen 49
Kunming 49
Bari 47
North Bergen 47
Redondo Beach 47
Miami 46
Verona 46
Falkenstein 45
Tashkent 45
Baghdad 41
Mumbai 41
Newark 41
Amsterdam 40
Totale 62.201
Salva come PNG Salva come JPEG
Nome #
VALORE PROGNOSTICO E PREDITTIVO DI p53 NEL CARCINOMA MAMMARIO TRATTATO CON CHEMIOTERAPIA NEOADIUVANTE 1.180
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO 509
Rigenerand srl - Spin off Università di Modena e Reggio Emilia 470
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 461
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 443
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study 443
Soluble TRAIL Armed Human MSC As Gene Therapy For Pancreatic Cancer 441
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 438
Phase I study of intraperitoneal MHC unrestricted adoptive cell therapy with TALL-104 cells in patients with peritoneal carcinosis 434
MSC-delivered soluble TRAIl and paclitaxel as novel combinatory treatment for pancreatic adenocarcinoma 433
GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion. 432
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. 430
Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy 421
MSC and Tumors: Homing, Differentiation and Secretion Influence The Therapeutic Potentials 411
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing 411
Cytogenetic abnormalities and clinical features in a patient cohort affected by three or more synchronous or metachronous primitive malignancies. 409
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. 405
MODULAZIONE DELL’ESPRESSIONE DI BIOMARCATORI E PROGNOSI IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO OPERABILE SOTTOPOSTE A CHEMIOTERAPIA PREOPERATORIA 403
Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood 403
Neoadjuvant treatment with Single – Agent Cetuximab Followed by 5-Fu, Cetuximab, and Pelvic Radiotherapy: A Phase II Study in Locally Advanced Rectal Cancer. 401
Predictors of human epidermal growth factor receptor 2 fluorescence in-situ hybridisation amplification in immunohistochemistry score 2+ infiltrating breast cancer: a single institution analysis. 399
SOLUBLE TRAIL-ARMED HUMAN AD-MSC AS NOVEL CELL THERAPY APPROACH FOR PANCREATIC DUCTAL ADENOCARCINOMA 398
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 398
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB) 394
Le Cellule Staminali Mesenchimali: Aspetti Biologici ed Approcci Terapeutici 390
Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus 377
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. 375
Mesenchymal progenitors aging highlights a mir-196 switch targeting HOXB7 as master regulator of proliferation and osteogenesis 373
Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer.. 371
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial . 371
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 362
Predictive and prognostic role of p53 according to tumor phenotype in breast cancer patients treated with preoperative chemotherapy: a single-institution analysis 361
Animal serum-free culture conditions for isolation and expansion of multipotent mesenchymal stromal cells from human BM 360
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer 354
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma 352
Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas 352
3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer 351
Proteasome inhibitors sensitize colon carcinoma cells to TRAIL-induced apoptosis via enhanced release of Smac/DIABLO from the mitochondria 345
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial 344
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. 343
Achievements and unmet needs in the management of advanced ovarian cancer 342
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 341
CHER LOB Trial: Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer--Safety report as per Independent Data Monitoring Committee (IDMC) and preliminary activity data 341
FOLFOX6 and bevacizumab in non-optimally resectable liver metastases from colorectal cancer 340
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 339
Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients 338
Prognostic and Predictive Value of Baseline and Posttreatment Molecular Marker Expression in Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy 338
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 333
METHOD FOR PRODUCTION OF ANTI-TUMOR TRAIL PROTEIN 332
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 330
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 329
Preoperative chemotherapy plus lapatinib or trastuzumab or both in Her2 positive operable breast cancer. EGF109085-LAP106988/CHERLOB Trial. 328
Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). 325
Rare breast cancer subtypes: Histological, molecular, and clinical peculiarities 324
Restoration and reversible expansion of the osteoblastic hematopoietic stem cell niche after marrow radioablation 324
Immune characterization of breast cancer metastases: prognostic implications. 323
5-Fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: A randomized phase II study in metastatic colorectal cancer 320
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study Short-HER. 320
Laparoscopic approach of gastric gastrointestinal stromal tumors (GISTs): Is it still a courageous choice? Report of two cases 319
Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer 315
A dose-finding study of ifosfamide by three-day continuous infusion in pretreated, advanced breast cancer patients. 314
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 313
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer 311
Donor Cell-Derived Osteopoiesis Originates from a Self-Renewing Stem Cell with a Limited Regenerative Contribution after Transplantation 306
Biomarker expression and survival after primary chemotherapy for breast cancer. 305
Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer 304
Primary adrenal gland carcinosarcoma associated with metastatic rectal cancer: a hitherto unreported collision tumor 302
A phase I-II study of oral doxifluridine plus radiotherapy in radiosensitive tumors of the pelvic region. 300
Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer 297
Prognostic value of "Dworak" tumor regression grade (TRG) after pre-operative chemo-radiotherapy in rectal cancer (RC) 293
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 293
Preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2 positive operable breast cancer: results of the randomized phase II CHER-LOB study 292
Gastrointestinal stromal tumor and other primary metachronous and synchronous neoplasms as a suspicious criterion for syndromic setting 290
Significance of lymph node sampling in epithelial carcinoma of the ovary. 290
PREVALENCE OF NODE NEGATIVE AND SMALL SIZE TUMORS IN A NATIONAL, RANDOMISED, PHASE III ADJUVANT TRIAL IN HER2 + EARLY BREAST CANCER (SHORT-HER STUDY) 290
Preliminary safety data of preoperative chemotherapy plus trastuzumab, lapatinib or both in HER2-positive operable breast cancer 289
PROLIFERATION AND APOPTOSIS BEFORE AND AFTER PRIMARY SYSTEMIC THERAPY FOR OPERABLE BREAST CANCER 287
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS 287
The curability of breast cancer and the treatment of advanced disease 285
Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy. 285
Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of After-6 protocol 1 282
Cardiotoxicity of Epirubicin/Paclitaxel Containing Regimens: Role of Cardiac Risk Factors 281
Evolving nonendocrine therapeutic options for metastatic breast cancer: how adjuvant chemotherapy influences treatment. 281
Intraperitoneal versus Intravenous Cisplatin in Combination with Intravenous Cyclophosphamide and Epidoxorubicin in Optimally Cytoreduced Advanced Epithelial Ovarian Cancer: A randomized trial of the Gruppo Oncologico Nord Ovest. 280
Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. 280
Paclitaxel and vinorelbine in anthracycline pretreated breast cancer: a phase II study. 276
Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. 274
Erratum to: Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2− breast cancer: results from two prospective trials (Breast Cancer Research and Treatment, (2017), 163, 2, (295-302), 10.1007/s10549-017-4191-y) 274
Trans-CHER-Lob: A Biomarker Analysis of the Randomized Phase II Study of Neoadjuvant Chemotherapy Plus Trastuzumab, Lapatinib or Combined Trastuzumab and Lapatinib in HER2 Positive Operable Breast Cancer. 273
Device for cell culture 272
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG 271
P53 EXPRESSION IS A SIGNIFICANT PREDICTOR OF RESPONSE AND PROGNOSIS IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 270
Biomarkers predicting clinical benefit: fact or fiction? 269
Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trial. 266
Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials 266
A phase II study with danazol in metastatic breast cancer. 265
Use of Ki-67 in residual disease following preoperative chemotherapy to predict of recurrence and death in breast cancer patients. 265
41. HER2+ EARLY BREAST CANCER: DO WE HAVE ALL THE NECESSARY ANSWERS? 264
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy 264
Varicella zoster virus reactivation in patients with breast cancer and multiple myeloma after autologous stem cell transplantation 263
Totale 34.718
Salva come PNG Salva come JPEG
Categoria #
all - tutte 336.233
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 336.233
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.417 0 0 0 382 147 259 445 325 648 469 962 780
2022/20236.351 741 573 316 510 659 906 77 541 1.521 83 257 167
2023/20243.774 182 248 204 229 705 349 393 705 125 114 163 357
2024/202511.504 362 159 183 872 2.139 1.812 493 761 1.480 780 1.022 1.441
2025/202625.948 1.329 1.003 2.221 3.016 3.369 2.034 2.813 1.440 2.168 2.625 2.172 1.758
2026/20276.795 1.011 1.759 2.615 1.410 0 0 0 0 0 0 0 0
Totale 89.320